Vanguard Group
PMVP icon

Vanguard Group’s PMV Pharmaceuticals PMVP Stock Holding History

Vanguard Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.71M Buy
2,170,310
+7,283
+0.3% +$9.76K ﹤0.01% 3463
2025
Q3 		$3.03M Buy
2,163,027
+9,427
+0.4% +$13K ﹤0.01% 3436
2025
Q2 		$2.28M Sell
2,153,600
-21,461
-1% -$21.1K ﹤0.01% 3497
2025
Q1 		$2.37M Buy
2,175,061
+31,959
+1% +$43.4K ﹤0.01% 3443
2024
Q4 		$3.24M Sell
2,143,102
-137,701
-6% -$218K ﹤0.01% 3421
2024
Q3 		$3.4M Sell
2,280,803
-1,287
-0.1% -$1.99K ﹤0.01% 3403
2024
Q2 		$3.7M Sell
2,282,090
-170,021
-7% -$307K ﹤0.01% 3377
2024
Q1 		$4.17M Buy
2,452,111
+46,804
+2% +$87.4K ﹤0.01% 3372
2023
Q4 		$7.46M Buy
2,405,307
+362,986
+18% +$961K ﹤0.01% 3113
2023
Q3 		$12.5M Buy
2,042,321
+7,288
+0.4% +$50.1K ﹤0.01% 2753
2023
Q2 		$12.7M Buy
2,035,033
+71,613
+4% +$375K ﹤0.01% 2810
2023
Q1 		$9.37M Sell
1,963,420
-790,186
-29% -$5.56M ﹤0.01% 2972
2022
Q4 		$24M Sell
2,753,606
-680,359
-20% -$7.25M ﹤0.01% 2537
2022
Q3 		$40.9M Buy
3,433,965
+78,001
+2% +$1.13M ﹤0.01% 2279
2022
Q2 		$47.8M Buy
3,355,964
+617,081
+23% +$8.98M ﹤0.01% 2213
2022
Q1 		$57M Buy
2,738,883
+90,937
+3% +$1.6M ﹤0.01% 2238
2021
Q4 		$61.2M Sell
2,647,946
-5,448
-0.2% -$132K ﹤0.01% 2239
2021
Q3 		$79.1M Buy
2,653,394
+411,683
+18% +$13.1M ﹤0.01% 2110
2021
Q2 		$76.6M Buy
2,241,711
+1,054,433
+89% +$35.2M ﹤0.01% 2140
2021
Q1 		$39M Buy
1,187,278
+28,771
+2% +$1.13M ﹤0.01% 2444
2020
Q4 		$71.3M Buy
1,158,507
+1,138,507
+5,693% +$44.7M ﹤0.01% 2019
2020
Q3 		$710K Buy
+20,000
New +$736K ﹤0.01% 3743

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group's PMVP Position: Q4 2025 in Review

Vanguard Group increased its PMV Pharmaceuticals (PMVP) stake by 0.34% in Q4 2025, buying an estimated $9.76K and bringing the position to 2,170,310 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3463.

Vanguard Group first reported a position in PMVP in Q3 2020 and has held it in 22 quarters since. The position peaked at $79.1M in Q3 2021. 63 funds tracked by Wall St. Rank hold PMVP as of Q4 2025.

  • Vanguard Group held 2,170,310 shares of PMV Pharmaceuticals worth $2.71M as of Q4 2025.
  • Vanguard Group bought 7,283 PMV Pharmaceuticals shares in Q4 2025, an estimated $9.76K.
  • PMV Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3463 holding.
  • Vanguard Group first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's PMV Pharmaceuticals position peaked at $79.1M in Q3 2021.
  • 63 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.